New HIV pill aims to control virus fast in untreated patients

NCT ID NCT07357584

First seen Jan 27, 2026 · Last updated May 12, 2026 · Updated 18 times

Summary

This study tests a three-drug pill (doravirine, lamivudine, tenofovir) for people newly diagnosed with HIV who have never taken HIV medication. The goal is to see if starting treatment quickly can lower the virus to undetectable levels by 48 weeks. About 100 adults will take the pill daily, and researchers will check how well it works and if it causes side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fundacion Huesped

    Buenos Aires, C1202ABB, Argentina

  • Fundacion IDEAA -Infectologia de atencion ambulatoria

    Ciudad Autonoma de Buenos Aire, Buenos Aires, C1405CKC, Argentina

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.